The primary objective was to evaluate the efficacy of ChAdOx1 nCoV-19 vaccine against NAAT-confirmed COVID-19. The primary outcome was virologically confirmed, symptomatic COVID-19, defined as a NAAT-positive swab combined with at least one qualifying symptom (fever ≥37·8°C, cough, shortness of breath, or anosmia or ageusia). All participants were given an emergency 24-h telephone number to contact the on-call study physician for the duration of the study to report any illnesses. Serious adverse events were recorded throughout the study and reviewed at each study visit, with causality assigned by the site investigator. Events were clinically coded according to the Medical Dictionary for Regulatory Activities.
Voysey M., Clemens S.A., Madhi S.A., Weckx L.Y., Folegatti P.M., Aley P.K., Angus B., Baillie V.L., Barnabas S.L., Bhorat Q.E., Bibi S., Briner C., Cicconi P., Collins A.M., Colin-Jones R., Cutland C.L., Darton T.C., Dheda K., Duncan C.J., Emary K.R., Ewer K.J., Fairlie L., Faust S.N., Feng S., Ferreira D.M., Finn A., Goodman A.L., Green C.M., Green C.A., Heath P.T., Hill C., Hill H., Hirsch I., Hodgson S.H., Izu A., Jackson S., Jenkin D., Joe C.C., Kerridge S., Koen A., Kwatra G., Lazarus R., Lawrie A.M., Lelliott A., Libri V., Lillie P.J., Mallory R., Mendes A.V., Milan E.P., Minassian A.M., McGregor A., Morrison H., Mujadidi Y.F., Nana A., O’Reilly P.J., Padayachee S.D., Pittella A., Plested E., Pollock K.M., Ramasamy M.N., Rhead S., Schwarzbold A.V., Singh N., Smith A., Song R., Snape M.D., Sprinz E., Sutherland R.K., Tarrant R., Thomson E.C., Török M.E., Toshner M., Turner D.P., Vekemans J., Villafana T.L., Watson M.E., Williams C.J., Douglas A.D., Hill A.V., Lambe T., Gilbert S.C, & Pollard A.J. (2021). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet (London, England), 397(10269), 99-111.
Other organizations :
University of Siena, South African Medical Research Council, Universidade Federal de São Paulo, Jenner Institute, Respiratory and Meningeal Pathogens Research Unit, University of the Witwatersrand, Stellenbosch University, Soweto CTC, Perinatal HIV Research Unit, Liverpool School of Tropical Medicine, University of Sheffield, Sheffield Teaching Hospitals NHS Foundation Trust, Groote Schuur Hospital, University of Cape Town, London School of Hygiene & Tropical Medicine, Newcastle University, Newcastle upon Tyne Hospitals NHS Foundation Trust, University of Southampton, NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, University Hospitals Bristol NHS Foundation Trust, University of Bristol, Guy's and St Thomas' NHS Foundation Trust, St Thomas' Hospital, MRC Clinical Trials Unit at UCL, University College London, University Hospitals Birmingham NHS Foundation Trust, Wellcome Trust, St George's, University of London, AstraZeneca (United Kingdom), North Bristol NHS Trust, UCL Biomedical Research Centre, University of Hull, Escola Bahiana de Medicina e Saúde Pública, Hospital São Rafael, D’Or Institute for Research and Education, Universidade Federal do Rio Grande do Norte, London North West Healthcare NHS Trust, Setshaba Research Centre, Universidade Unigranrio, NIHR Imperial Biomedical Research Centre, Universidade Federal de Santa Maria, University of Glasgow, Boston Children's Hospital, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Western General Hospital, Queen Elizabeth University Hospital, MRC University of Glasgow Centre for Virus Research, University of Cambridge, Cambridge University Hospitals NHS Foundation Trust, Papworth Hospital NHS Foundation Trust, Nottingham University Hospitals NHS Trust, University of Nottingham, Public Health Wales, Aneurin Bevan University Health Board
Virologically confirmed, symptomatic COVID-19 (NAAT-positive swab combined with at least one qualifying symptom: fever ≥37·8°C, cough, shortness of breath, or anosmia or ageusia)
Serious adverse events
control variables
All participants were given an emergency 24-h telephone number to contact the on-call study physician for the duration of the study to report any illnesses.
positive controls
Not explicitly mentioned
negative controls
Not explicitly mentioned
Annotations
Based on most similar protocols
Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to
get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
